Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 586-600

  Verheggen, Bram G ^a   Lee, Richard ^b   Lieuw On, Michelle M ^a   Treur, Maarten J ^a   Botteman, Marc F ^c   Kaplan, Steven A ^b   Trocio, Jeffrey N ^d  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b Cornell University ^*  (United States)

^c PHARMERIT INTERNATIONAL   (United States)

^d PFIZER INC   (United States)

Author keywords

Cost effectiveness; Lower urinary tract symptoms; Overactive bladder; Prostatic hyperplasia; Tamsulosin; Tolterodine; United Kingdom

Indexed keywords

PLACEBO; TAMSULOSIN; TOLTERODINE;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LENGTH OF STAY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOCTURIA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PROSTATE HYPERTROPHY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT DURATION; URGE INCONTINENCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; STATE MEDICINE; URINARY BLADDER, OVERACTIVE; URINATION DISORDERS;

EID: 84859195407     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.666511     Document Type: Article

References (28)

1. Chapple CR. Introduction and conclusions. Improving the management of lower urinary tract symptoms in real life practices. Eur Urol 2001;39(3 Suppl):1-5
2. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: Bladder, outlet, or both? Curr Urol Rep 2002;3:445-51
3. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006;49:651-9
4. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-The Triumph project. Eur Urol 2002;42:323-8
5. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
6. Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9
7. van Exel NJ, Koopmanschap MA, McDonnell J, et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: Report of the TRIUMPH study. Eur Urol 2006;49:92-102
8. Polder JJ, Meerding WJ, Koopmanschap MA, et al. [The cost of sickness in the Netherlands in 1994; the main determinants were advanced age and disabling conditions]. Ned Tijdschr Geneeskd 1998;142:1607-11
9. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006;296:2319-28
10. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prospective, randomized, controlled multicenter study. J Urol 2005;174:1334-8
11. Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20
12. Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005;6:2429-33
13. de la Rosette J, Alivizatos G, Madersbacher S, et al. Guidelines on Benign Prostatic Hyperplasia. Arnhem: European Association of Urology, 2009
14. AUA BPH Guideline Update Panel. AUA guideline on the management of benign prostatic hyperplasia: Diagnosis and treatment recommendations. Linthicum: AUA Guideline on the Management of Benign Prostatic Hyperplasia (BPH), 2003
15. Tkocz M, Prajsner A. Comparison of long-Term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. Neurourol Urodyn 2002;21:112-6
16. Mattiasson A, Wagrell L, Schelin S, et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: A prospective randomized multicenter study. Urology 2007;69:91-6; discussion 6-7
17. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-60
18. Ware Jr. J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33
19. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-108
20. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29
21. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. http://bnf.org/bnf/index.htm. Accessed January 2010
22. UK Office for National Statistics. Consumer price index figures. http://www.statistics.gov.uk/statbase/tsdataset.asp?vlnk7174&MoreY. Accessed January 2010
23. Department of Health. National Health Service Reference Costs 2008-2009. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH-111591. Accessed January 2010
24. Speakman M, Khullar V, Mundy A, et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-9
25. Hakkaart L, Verboom P, Phillips R, et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009;41:293-8
26. McDonnell J, Busschbach JJ, Kok E, et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction-Triumph: health-economical analysis. Eur Urol 2001;39(3 Suppl):37-41
27. DiSantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int 2006;97:1007-16
28. DiSantostefano RL, Biddle AK, Lavelle JP. The long-Term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 2006; 24:171-91